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Identiﬁcation of genes associated with hereditary cancers
facilitates management of patients with family histories of
cancer. We performed exome sequencing of DNA from 3 in-
dividuals from a family with colorectal cancer who met the
Amsterdam criteria for risk of hereditary nonpolyposis
colorectal cancer. These individuals had mismatch repair-
proﬁcient tumors and each carried nonsense variant in the
FANCD2/FANCI-associated nuclease 1 gene (FAN1), which
encodes a nuclease involved in DNA inter-strand cross-link
repair. We sequenced FAN1 in 176 additional families with
histories of colorectal cancer and performed in vitro func-
tional analyses of the mutant forms of FAN1 identiﬁed. We
detected FAN1 mutations in approximately 3% of families
who met the Amsterdam criteria and had mismatch repair-
proﬁcient cancers with no previously associated mutations.
These ﬁndings link colorectal cancer predisposition to the
Fanconi anemia DNA repair pathway, supporting the
connection between genome integrity and cancer risk.
Keywords: Lynch Syndrome; Genetic Risk Factor; Susceptibility;
DNA Mismatch Repair.
amilial aggregation of colorectal cancer (CRC) is one0016-5085
http://dx.doi.org/10.1053/j.gastro.2015.05.056Fof the strongest risk factors for CRC. Germline mu-
tations in the DNA mismatch repair (MMR) genes, EPCAM,APC, MUTYH, POLE, POLD1, GREM1, SMAD4, BMPR1A, STK11,
and PTEN cause hereditary forms of CRC.13 However, part
of the observed heritability and familial aggregation of the
disease is yet to be explained.
With the aim of identifying new hereditary CRC genes,
we sequenced the exomes of 3 cancer-affected members of
a high-risk, Amsterdam I MMR-proﬁcient, CRC family
(Figure 1A, Family 1). Of 32 unreported or rare (minor allele
frequency <1%) nonsynonymous variants shared by all
affected relatives (Supplementary Table 1), a nonsense
mutation in FAN1, c.141C>A (p.C47*) deserved our atten-
tion, as the coded protein, FANCD2/FANCI-associated
nuclease 1 (MIM# 613534), is involved in interstrand
cross-link repair (Fanconi anemia [FA]) and interacts with
MMR components, such as MLH1, PMS2 and PMS1, thus
playing a role in maintaining genome integrity.48 The
identiﬁed FAN1 mutation had not been reported previously
(NHLBI GO Exome Sequencing Project [ESP], 1000 Genomes
Project) or found in 1648 alleles of Spanish origin, including
Figure 1. (A) Pedigrees of the families with germline FAN1 mutations. Filled symbol, cancer; þ, mutation carrier; (þ), obliged
mutation carrier; , wild-type; arrow, index case. Ages at information gathering or at death, when available, are indicated on
the top-left corner of each individual’s symbol. Ca., cancer; GI, gastrointestinal; mtx, metastasis; unk, unknown location.
(B) MMC sensitivity assay with the FAN1 knockout HEK293T cell line stably transfected with a pUltra empty vector (EV), the
vector with wild-type FAN1 (WT), and the vector with c.418G>T (p.D140Y)-mutated FAN1.
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phenotype shows lower sensitivity to mitomycin C (MMC)
than other FA genes.9 Even so, heterozygous c.141C>A
(p.C47*) cells showed higher sensitivity to relatively high
doses of MMC (1070 nM) than wild-type cells
(Supplementary Figure 1).
Four additional unreported or rare genetic variants in
FAN1 were identiﬁed in 176 MMR-proﬁcient Amsterdam-
positive families: a truncating mutation, c.2854C>T
(p.R952*), and 3 missense variants, c.418G>T (p.D140Y),
c.1018C>T (p.P340S), and c.1771C>T (p.R591W). Mutation
carrier status could be assessed in 15 members of the FAN1-
mutated families: all cancer-affected (10 CRC and 1 breast
cancer) and 3 unaffected 21-, 43-, and 47-year-old in-
dividuals were carriers, and 1 unaffected 53-year-old was a
noncarrier (Figure 1A). No exonic or splice-site variants
were identiﬁed in 71 MMR-proﬁcient Bethesda CRC families,
in the normal colonic mucosae of 42 Spanish sporadic CRC
patients and of 100 CRC patients from The Cancer Genome
Atlas (TCGA),10 and in 250 Spanish individuals without
CRC.11 However, among the 6503 ESP individuals, a total of
10 nonsense, frameshift or splice-site FAN1 variants with
minor allele frequency <1%, were identiﬁed in 16 subjects
(0.24%). Unfortunately, no information about personal or
family history of cancer is available. The limited number of
mutation carriers identiﬁed (n ¼ 14), together with the
ascertainment bias due to the study of mostly cancer-
affected family members, hampers at this point the esti-
mation of risks and penetrance.
The identiﬁcation of 2 truncating mutations in FAN1
prompted us to investigate whether the other 3 variants
might also affect the protein function. In silico algorithms
predicted damaging functional effects for p.R591W and
p.D140Y (Table 1). p.R591W, located in an evolutionary
conserved residue, is also predicted to destabilize the pro-
tein structure, being localized in an exposed loop that con-
nects 2 a-helices in the vicinity of the DNA-binding (SAP)
domain (Supplementary Figure 2). c.418G>T (p.D140Y) is
located in the ﬁrst traduced exon, which codes for the UBZ
domain, essential for FAN1 localization to sites of damage.7
Heterozygous c.418G>T (p.D140Y) cells showed similar
sensitivity to MMC than heterozygous c.141C>A (p.C47*)
(Supplementary Figure 3), suggesting functional implica-
tions for c.418G>T. To conﬁrm this, we generated a FAN1
knockout HEK293T cell line that recapitulated the
MMC-sensitive phenotype observed in FAN1/ cells
(Supplementary Figure 4), and stably transfected it with
wild-type FAN1, c.418G>T-mutated FAN1 and the empty
vector. The c.418G>T-transfected cell line showed the same
level of sensitivity to MMC as the empty vector (Figure 1B)
without affecting FAN1 protein expression (Supplementary
Figure 5), strongly suggesting that the missense mutation
causes an DNA interstrand cross-link repair defect.
Five colorectal tumors developed by FAN1 mutation
carriers (3 c.141C>A and 2 c.418G>T) were available for
somatic testing. Whole-exome sequencing of the Family 1
proband’s tumor identiﬁed a total of 236 somatic mutations
in transcribed sequences (Supplementary Table 2), with a
mean mutation rate of 5/Mb, or 1.3/Mb for nonsynonymous
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nonhypermutant CRCs.10 However, the mutation spectrum
is characterized by an excess of T:A>G:C (10.5%) and
C:G>G:C transversions (12.5%), both exceeding the 95th
percentiles observed in nonhypermutant TCGA CRCs
(Supplementary Figure 6). On the other hand, no clear evi-
dence of somatic FAN1 second hits was obtained: no loss of
heterozygosity (0/5) or somatic mutation (0/3)
(Supplementary Figure 7). In addition, neither loss of RNA
expression of the wild-type allele nor reduction of expres-
sion of the FAN1 protein was observed in the tumor
developed by a c.141C>A (p.C47*) carrier. However, FAN1
protein levels of normal colon mucosa from the FAN1
c.141C>A carrier were lower than those of a wild-type in-
dividual (Supplementary Figure 8). These observations,
together with the deﬁcient DNA interstrand cross-link
repair observed in lymphoblastoid cells from heterozygous
mutation carriers (Supplementary Figures 1 and 3), suggest
that FAN1 haploinsufﬁciency might cause a bias toward a
speciﬁc type of error due to defective DNA maintenance.
FAN1 interacts with MMR proteins and the nuclease
function is required for fully functional MMR.7,8,12 However,
as MMR proﬁciency is an inclusion criteria in our study,
tumors developed by FAN1 mutation carriers showed mi-
crosatellite stability and/or normal expression of MMR
proteins (Supplementary Figure 9). The fact that a plethora
of nucleases, including FAN1, EXO1, and MRE11, can carry
out the required nuclease activity for the MMR function12
might explain the absence of MMR deﬁciency in FAN1 mu-
tation carriers’ tumors.
FAN1 deﬁciency causes distinct milder phenotypes than
other components of the FA pathway. Biallelic loss of FAN1
does not cause FA, but karyomegalic interstitial nephritis
(MIM# 614817), a very rare recessive disease (approxi-
mately 20 families reported so far) characterized by slow
progressive renal failure that leads to end-stage renal dis-
ease before age 50 years.13 Despite the lack of information
on cancer history of monoallelic carriers, development of
cancer at early ages has been described in 2 families: an
autopsy performed in a 30-year-old individual with
karyomegalic interstitial nephritis revealed a rectal adeno-
carcinoma, and another affected individual died of hepato-
cellular carcinoma at age 22 years.14,15 Interestingly,
although karyomegalic interstitial nephritisassociated
biallelic mutations in FAN1 localize toward the C-terminus
of the protein, after the SAP domain, monoallelic mutations
associated with hereditary CRC do not show preferential
gene location (Supplementary Figure 10).7
Our ﬁndings implicate FAN1 mutations in the inherited
susceptibility to CRC. The analysis of larger familial CRC
series will provide information about the prevalence of
FAN1 mutations (2.8% of Amsterdam-positive MMR-proﬁ-
cient families in our series) and allow the estimation of
lifetime cancer risks for mutation carriers. Likewise, a
thorough analysis of genetic and genomic alterations found
in FAN1-associated tumors will clarify the underlying repairdefects accumulated and, therefore, the mechanism of action
of FAN1 in colorectal carcinogenesis. Our ﬁndings further
support the relationship between defective DNA repair and
cancer predisposition, providing the ﬁrst unequivocal evi-
dence linking the FA pathway and CRC through FAN1, a
bridge between FA and MMR DNA repair pathways.Supplementary Material
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